ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoan Lamarche
Raymond Cartier
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamarche, Y.
Right arrow Articles by Bonan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamarche, Y.
Right arrow Articles by Bonan, R.
Related Collections
Right arrow Valve disease

Ann Thorac Surg 2007;83:284-287
© 2007 The Society of Thoracic Surgeons

Case Reports

Implantation of the CoreValve Percutaneous Aortic Valve

Yoan Lamarche, MDa, Raymond Cartier, MDa, André Y. Denault, MDb, Arsène Basmadjian, MDc, Colin Berry, MD, PhDa, Jean-Claude Laborde, MDd, Raoul Bonan, MDc,*

a Department of Surgery, Montréal Heart Institute and "Université de Montréal," Montréal, Québec, Canada
b Department of Anesthesiology, Montréal Heart Institute and "Université de Montréal," Montréal, Québec, Canada
c Department of Cardiology, Montréal Heart Institute and "Université de Montréal," Montréal, Québec, Canada
d Department of Cardiology, Clinique Pasteur, Toulouse, France

Accepted for publication May 31, 2006.

* Address correspondence to Dr Bonan, Department of Medicine, Montréal Heart Institute, 5000 Belanger St, Montréal, Québec H1T1C8, Canada (Email: raoul.bonan{at}mmic.net).

Surgical aortic valve replacement is the only recommended treatment for significant aortic valve stenosis. Percutaneous aortic valve replacement appears to be a novel option for high-risk patients. We report the implantation of the ReValving system (CoreValve, Paris, France) in a 64-year-old woman who was refused aortic valve replacement surgery for critical aortic stenosis and left ventricular dysfunction because of severe pulmonary fibrosis. After anesthesia, the patient was put on femorofemoral cardiopulmonary bypass, and underwent a balloon valvuloplasty with subsequent retrograde aortic valve replacement by the ReValving system. Transesophageal echocardiographic monitoring of the patient’s hemodynamics showed immediate improvements of the valvular area and left ventricular ejection fraction and only traces of paravalvular leaks. The patient was easily weaned from ventilation and resumed activity soon after the surgery. A multidisciplinary approach is presently necessary to offer a reliable and safe procedure.




This article has been cited by other articles:


Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
B. Qizilbash, P. Couture, and A. Denault
Impact of Perioperative Transesophageal Echocardiography in Aortic Valve Replacement
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 288 - 300.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
B. Marcheix, Y. Lamarche, C. Berry, A. Asgar, J.-C. Laborde, A. Basmadjian, A. Ducharme, A. Denault, R. Bonan, and R. Cartier
Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis.
J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1150 - 1156.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The Society of Thoracic Surgeons.